Definium Therapeutics, Inc. (DFTX) has an average rating of buy and mean price target of $60, according to analysts polled by FactSet.
What else is happening in Research?
Research
UBS Downgrades SFS Group to Neutral, Lifts PT
UBS on Friday downgraded Swiss precision components and fastening technology company SFS Group (SFSN.SW) to neutral from buy and increased its price target to 145 francs from 130 francs.
$SFSN.SW
Research
BNP Paribas Downgrades Wienerberger to Neutral, Cuts PT
BNP Paribas on Friday downgraded building materials company Wienerberger (WIBA.F) to neutral from outperform and reduced its price target to 20 euros from 27 euros.
$WIBA.F
Research
AlphaValue/Baader Europe Upgrades Informa to Buy, Lifts PT
AlphaValue/Baader Europe on Friday upgraded British events, digital services, and academic research group Informa (INF.L) to buy from add and raised its price target to 11.56 pounds sterling from 11.46 pounds.
$INF.L